Azacitidine
Myelodysplastic Syndrome/Acute Myeloid Leukemia
City of Hope Medical CenterSmall moleculePhase 2/3Active
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 89/ 100
Competitive context
18 Active assets in the Myelodysplastic Syndrome/Acute Myeloid Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Decitabine National Cancer Institute (NCI) | Phase 2/3 | B |
Cytosin-Arabinosid National Cancer Institute (NCI) | Phase 2/3 | B |
Nivolumab National Cancer Institute (NCI) | Phase 2/3 | B |
Midostaurin National Cancer Institute (NCI) | Phase 2/3 | B |
Thiotepa Fred Hutchinson Cancer Center | Phase 2 | CCC |
View all 21 →
Same molecule, other indications
Azacitidine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →